203.6600 1.23 (0.61%)
NSE Jul 04, 2025 15:31 PM
Volume: 5.9M
 

ICICI Securities Limited
Piramal Pharma’s (PPL) Q2FY23 performance was driven by growth across its business segments. Revenue grew 9.0% YoY (+16% QoQ) to Rs17.2bn.
Number of FII/FPI investors decreased from 266 to 257 in Mar 2025 qtr
More from Piramal Pharma Ltd.
Recommended